| Code | CSB-RA001950MB7HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Crenezumab, targeting amyloid precursor protein (APP). APP is a transmembrane protein that plays critical roles in neuronal development, synaptic plasticity, and cell signaling. Proteolytic processing of APP by β- and γ-secretases generates amyloid-beta (Aβ) peptides, which aggregate to form the characteristic amyloid plaques observed in Alzheimer's disease. Aberrant APP processing and accumulation of toxic Aβ oligomers and fibrils contribute to neurodegeneration, synaptic dysfunction, and cognitive decline, making APP a central target in Alzheimer's disease research.
Crenezumab is a humanized IgG4 monoclonal antibody originally developed to bind multiple forms of Aβ, including monomers, oligomers, and fibrils, with particular affinity for oligomeric species. This biosimilar antibody provides researchers with a valuable tool for investigating APP biology, amyloid pathology, and potential therapeutic mechanisms in neurodegenerative disease models. It supports studies examining protein-protein interactions, cellular localization, and the role of APP and its cleavage products in disease pathogenesis.
There are currently no reviews for this product.